On 17 February 2016, orphan designation (EU/3/16/1616) was granted by the European Commission to Professor Michael Hanna, United Kingdom, for diclofenamide for the treatment of periodic paralysis.
The sponsorship was transferred to Giampietro Schiavo, Italy in April 2021.
Treatment of periodic paralysis
|Date of designation||
|Orphan designation status||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.